Over the past days, there have been considerable developments in two key health policies: the 340B drug pricing program and site-neutral payments. The Health Resources and Service Administration (HRSA) has begun sending letters to drug manufactures informing them they are in direct violation of the 340B statute. Meanwhile, Health and Human Services (HHS) has sent a brief to the Supreme Court urging the SCOTUS to uphold site-neutral payments as established in the 2017 Outpatient Prospective Payment System, after a lawsuit brought on by a hospital group challenged the validity of the regulation. For an overview of the 340B program and site-neutral payment systems, their current legal hurdles and what recent developments mean moving forward, keep reading. Read More >>>

Or open document to read more; page 3.

View PDF